[PDF] cancerbiomed.org

Polymorphisms of ERCC1, XPD, XRCC1 and XPG predict clinical outcome in advanced gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese …

J Jiang, J Liang, R Yao, Q Li, S Song, Y Sun - Clinical Oncology and …, 2009 - Springer
Objective To investigate whether polymorphisms in ERCC1, XPD, XPG, XRCC1 genes are
associated with clinical outcomes in advanced gastric cancer (AGC) patients treated with …
Save Cite Cited by 2 Related articles All 7 versions

Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based …

J Liang, QF Li, RY Yao, HY Lü, J Jiang… - Zhonghua Zhong liu …, 2010 - europepmc.org
Objective To evaluate the association between the polymorphisms of excision repair cross
complementation group 1 (ERCC1), X-ray repair cross complementing 1 (XRCC1) …
Save Cite Cited by 11 Related articles All 4 versions Cached
[HTML] nih.gov

[HTML][HTML] Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy

L Zhang, R Yao, S Fang, X Wang… - International journal of …, 2015 - ncbi.nlm.nih.gov
The aim of the present study was to evaluate the clinical outcome of excision repair cross-
complementing protein 1 (ERCC1) and X-ray repair cross-complementing protein 1 …
Save Cite Cited by 3 Related articles All 5 versions

XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis

X Zhang, LP Jiang, Y Yin, YD Wang - Tumor Biology, 2014 - Springer
This meta-analysis aimed to obtain a comprehensive and reliable assessment of the
relationships between XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms and the …
Save Cite Cited by 15 Related articles All 6 versions
[HTML] nature.com

[HTML][HTML] Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

B Liu, J Wei, Z Zou, X Qian, T Nakamura… - European journal of …, 2007 - nature.com
Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical
benefit to particular regimens. Platinum agents have shown to be effective in the treatment of …
Save Cite Cited by 87 Related articles All 12 versions

ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy

J Wei, B Liu, Z Zou, X Qian, W Zhang… - Journal of Clinical …, 2007 - ascopubs.org
2512 Background: DNA repair was considered to play the key role in the platinum
chemotherapy. ERCC1, XPD and XRCC1, three major components of the DNA repair …
Save Cite Cited by 7 Related articles

Comprehensive analysis of ERCC, XPD, and XRCC polymorphisms: association with clinical outcomes in patients with advanced gastric cancer

B Keam, H Kim, S Im, H Ham, S Han, E Cho… - Journal of Clinical …, 2007 - ascopubs.org
4649 Background: Platinum-DNA adducts are repaired by nucleotide excision repair (NER)
pathway, in which genes of the excision repair cross-complementation 1 (ERCC1) …
Save Cite Cited by 4 Related articles
[HTML] spandidos-publications.com

[HTML][HTML] Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin …

YP Liu, Y Ling, QF Qi, YP Zhang… - Molecular …, 2013 - spandidos-publications.com
The aim of the present study was to determine whether specific molecular parameters may
serve as predictors of treatment outcomes and toxicity of oxaliplatin (OXA)‑based …
Save Cite Cited by 32 Related articles All 11 versions
[HTML] astr.or.kr

[HTML][HTML] Chemotherapeutic responsibility according to polymorphism of ERCC1, XRCC1 and GSTP1 in gastric cancer patients receiving oxaliplatin based …

DY Won, SH Kim, H Hur, H Jung, HM Jeon - Journal of the Korean Surgical …, 2010 - astr.or.kr
Purpose The platinum-based modified FOLFOX-6 has been reported as an acceptable
chemotherapeutic regimen in treatment of advanced gastric cancer patients. The response …
Save Cite Cited by 6 Related articles All 15 versions Cached
[HTML] nih.gov

ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta …

M Yin, J Yan, E Martinez-Balibrea, F Graziano… - Clinical cancer …, 2011 - AACR
Purpose: Nucleotide excision repair (NER) modulates platinum-based chemotherapeutic
efficacy by removing drug-produced DNA damage. To summarize published data on the …
Save Cite Cited by 195 Related articles All 12 versions